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Assemblies of huntingtin (HTT) fragments with expanded polyglutamine (polyQ) tracts are a pathological hallmark of
Huntington’s disease (HD). The molecular mechanisms by which these structures are formed and cause neuronal dysfunc-
tion and toxicity are poorly understood. Here, we utilized available gene expression data sets of selected brain regions of HD
patients and controls for systematic interaction network filtering in order to predict disease-relevant, brain region-specific
HTT interaction partners. Starting from a large protein–protein interaction (PPI) data set, a step-by-step computational fil-
tering strategy facilitated the generation of a focused PPI network that directly or indirectly connects 13 proteins potentially
dysregulated in HD with the disease protein HTT. This network enabled the discovery of the neuron-specific protein CRMP1
that targets aggregation-prone, N-terminal HTT fragments and suppresses their spontaneous self-assembly into proteotoxic
structures in various models of HD. Experimental validation indicates that our network filtering procedure provides a simple
but powerful strategy to identify disease-relevant proteins that influence misfolding and aggregation of polyQ disease
proteins.
[Supplemental material is available for this article.]
Huntington’s disease (HD) is an inherited neurodegenerative dis-
order characterized by motor impairment and progressive neuro-
psychiatric changes (Harper 1996). It is caused by an expanded
polyglutamine (polyQ) tract in huntingtin (HTT), a large, ubiqui-
tously expressed, multidomain protein with multiple cellular
functions (Harjes and Wanker 2003). The elongated polyQ se-
quence is believed to confer a toxic gain of function to HTT, lead-
ing to a selective neurodegenerative disease phenotype primarily
in patient brains (DiFiglia et al. 1995).
A hallmark of HD pathology is the accumulation of insoluble
aggregates that are formed of N-terminal HTT fragments (DiFiglia
et al. 1997). Aggregates of HTT in the brains of patients and trans-
genic animals are sequestered into nuclear and cytoplasmic inclu-
sions. These structures also contain molecular chaperones or
components of the ubiquitin proteasome system involved in cellu-
lar defensemechanisms (Ciechanover and Brundin 2003). This as-
sociation, as well as the fact that the formation of inclusion bodies
correlates withmotor impairment in HD transgenicmice, suggests
that inclusionswith large insoluble HTT aggregates are harmful for
neuronal cells (Yamamoto et al. 2000). Alternatively, evidence has
been provided that the toxic species in HD may be diffusible oli-
gomeric or protofibrillar HTT aggregates with pathogenic polyQ
tracts (Hands andWyttenbach 2010). In contrast to large inclusion
bodies, these smaller structures are described as highly mobile and
able to associatewithnumerous cellular proteins, leading to abnor-
mal protein–protein interactions and dysfunction of a range of im-
portant cellular processes (Miller et al. 2011).
In any case, the molecular mechanisms by which toxic,
polyQ-containing HTT protein complexes and aggregates form
in neuronal cells and cause selective dysfunction and toxicity re-
main unclear (Hands and Wyttenbach 2010). Various studies
have demonstrated that polyQ tracts with about 40 or more
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glutamine residues drive the spontaneousmisfolding and aggrega-
tion of N-terminal HTT fragments in cell-free and cell-based assays
(Scherzinger et al. 1997; Waelter et al. 2001). This is supported by
investigations in Caenorhabditis elegans, which show that GFP-
tagged fusion proteins with long polyQ tracts (more than 40 gluta-
mines) form inclusion bodies much more efficiently than fusion
proteins with short polyQ tracts (20–35 glutamines) (Morley
et al. 2002). Initially, it was suggested that the spontaneous mis-
folding and aggregation of HTT fragments is initiated by hydrogen
bonds that stabilize intermolecular interactions between polyQ
tracts (Perutz et al. 1994). More recent studies, however, indicate
that polyQ flanking sequences, rather than the polyQ tracts them-
selves, initiate spontaneous HTT protein aggregation (Saunders
and Bottomley 2009). For instance, it was shown that the first
17 amino acids in HTT, which adopt an α-helical conformation,
can initiate the spontaneous aggregation of pathogenic polyQ
tracts in cell-free assays (Thakur et al. 2009). The importance of
this polyQ flanking sequence for HTT misfolding is supported by
biochemical studies with a chaperonin, which directly binds to
the first 17 amino acids of HTT and blocks the de novo aggregation
of N-terminal HTT fragments (Tam et al. 2009). Thus, proteins that
directly associate with polyQ flanking regions appear to strongly
influence the spontaneous polymerization of disease proteins.
Potential modifiers of mutant HTT aggregation expressed in
neurons may be waiting to be discovered in the large number of
proteins that associate with N-terminal polyQ-containing HTT
fragments in yeast two-hybrid (Y2H) or coimmunoprecipitation
assays (Goehler et al. 2004; Kaltenbach et al. 2007). The challenge
has been to distinguish modifiers with relevance to disease from
other interaction partners. Several observations may be helpful
in meeting this challenge. First, neuronal cell death in HD occurs
predominantly in particular brain regions. Second, disease-causing
mutations can lead to perturbations in the PPI networks in affected
tissues, thereby influencing pathogenesis. Changes in functional
protein interactions are frequently linked to changed protein
levels in cells; both phenomena have been shown to favor sponta-
neous protein misfolding and are indicators that a protein might
influence HTT aggregation and HD pathogenesis (Pechmann
et al. 2009; Vavouri et al. 2009). Therefore, we reasoned that HTT
interaction partners displaying abnormal changes in abundance
in regions of the brain that are particularly vulnerable to HD
may be disease-relevant modifiers that influence mutant HTTmis-
folding and aggregation.
To identify them, we developed a simple but powerful com-
putational procedure. We exploited published gene expression
data obtained from specific brain regions and HD patients to carry
out a step-by-step filtering of a large HTT PPI network that includes
more than 500 known interaction partners directly or indirectly
linked to HTT. By applying sequential interaction network filter-
ing, we defined 13 HTT-associated human proteins whose expres-
sion in the caudate nucleus of HD patient brains is likely to be
abnormal. Evaluation of available data and focused confirmation
studies enabled the discovery of the protein collapsin responseme-
diator protein 1 (CRMP1), a neuron-specific phosphoprotein that
plays a central role in neuronal development and communication
(Charrier et al. 2003). Levels of CRMP1 transcription were abnor-
mally low in the brains of HD patients. Experimental studies in
cell model systems revealed that overproduction of CRMP1 signif-
icantly reduces both misfolding and toxicity of mutant HTT,
whereas down-regulating the protein using siRNA had the op-
posite effect. We confirmed these findings in a Drosophila mela-
nogaster model of HD. Further investigations in cell-free assays
revealed that CRMP1 directly targets aggregation-prone HTT mol-
ecules and reduces their propensity to spontaneously self-assemble
into insoluble amyloid structures. A mutant, nonfunctional
CRMP1 protein (D408V) did not produce this effect. Thus, our re-
sults indicate that CRMP1 acts as a chaperone-like protein in neu-
ronal cells, where it associates with polyQ-containing HTT and
reduces its conversion into proteotoxic protein aggregates. This
has implications for HD pathogenesis and the development of
therapeutic strategies. More generally, our experimental results
confirm our computational network filtering procedure to be
highly valuable to identify disease-relevant proteins. It can be ap-
plied for interaction network analysis and the identification of ag-
gregation modulators in a wide variety of diseases.
Results
Application of a sequential interaction network filtering
strategy to predict brain region-specific, dysregulated
HTT-associated proteins
To identify disease-relevant proteins that influence mutant HTT
misfolding and aggregation in neurons among the large number
of already published HTT interaction partners (Chaurasia et al.
2009), we developed a computational procedure for prioritization
of interactions. It is based on the systematic integration of protein
interaction datawith gene expression data obtained fromdifferent
brain regions of healthy controls and HD patients (Supplemental
Tables S1–S9). Starting from a large HTT interaction network
with more than 500 partner proteins, we performed a three-step
interaction network filtering procedure in order to arrive at a
relatively small and focused HTT interaction network, in which
potentially dysregulated HTT interaction partners should be en-
riched (Fig. 1A,B). Such a network should facilitate focused fol-
low-up validation studies and the identification of modulator
proteins that are supposed to directly influence HTT misfolding
and aggregation.
In step I, we created a HTT-centric protein interaction net-
work (PPI1), using information from the literature (Goehler et al.
2004; Chaurasia et al. 2009). This network comprised 1319 interac-
tions in which 509 proteins were directly or indirectly linked to
HTT (Supplemental Table S2A,B). In order to generate a network
of human proteins that are potentially altered in their abundance
in comparison to nonbrain tissues, we filtered PPI1 for HTT inter-
action partners that are differentially expressed in healthy human
brain compared to nonbrain tissues (ΔEG1, P1 < 10
−4) (Supplemen-
tal Table S3). This resulted in the brain-specific network PPI2 (Fig.
1A), which consists of 113 interactions. In PPI2, 88 human pro-
teins are directly or indirectly linked to the disease protein HTT
(Supplemental Table S4A,B).
HD affects the whole brain, but certain areas such as the cau-
date nucleus are more vulnerable than others (Vonsattel et al.
1985).We therefore generated a brain region-specific protein inter-
action network in step II of the filtering procedure. We defined
genes as differentially expressed in the caudate nucleus (CN) by
comparison to motor cortex (MC), prefrontal cortex (PFC), and
cerebellum (CE), again using publicly available gene expression
profiles for healthy brain regions (ΔEG2, P2 < 10
−3) (Fig. 1A; Supple-
mental Table S5). This filtering step yielded PPI3, a network with
caudate nucleus proteins that are potentially altered in their abun-
dance in comparison to other brain regions. This network con-
nects 66 human proteins via 84 interactions directly or indirectly
to HTT (Fig. 1A; Supplemental Table S6A,B).
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Previous studies suggested that
dysregulated HTT-interacting proteins
might influence the propensity of HTT
to misfold and self-assemble into insol-
uble protein aggregates (Goehler et al.
2004; Behrends et al. 2006). In step III
of the filtering procedure we therefore
searched for HTT-associated proteins
dysregulated in HD patient brains. In a
comparison of gene expression profiles
from 38 HD patients and 32 healthy in-
dividuals (Supplemental Table S1), we
identified human genes that are differen-
tially expressed in the caudate nucleus
of HD patients and healthy individuals
(ΔEG3, P3 < 10
−6) (Fig. 1A; Supplemental
Table S7). This set was then utilized to fil-
ter the PPI3 network to yield the final, HD
dysregulated caudate-nucleus-specificHTT
interaction network PPI4 (Fig. 1A; Supple-
mental Table S8A,B). The result is a net-
work of 13 proteins that are directly or
indirectly linked to the disease-causing
protein HTT and that might be dysregu-
lated in their abundance based on the
available gene expression data in HD pa-
tients compared to controls (Fig. 1B). The
transcripts of seven proteins were found
to be abnormally up-regulated in brains
of HD patients, whereas six were down-
regulated (Fig. 1B; Supplemental Table S9).
The significance thresholds (P1, P2,
P3) for defining differential expression
(steps I–III) (Fig. 1A) were derived by
optimization with respect to an indepen-
dently generated reference set of validat-
ed HD therapy targets (HDTTs) from the
HD Research Crossroads database (Kala-
thur et al. 2012). This reference set was
curated by experts in the field and consti-
tutes the most comprehensive collection
of HDTTs to date. For optimization of the
significance thresholds, we hypothesized
that the relative number of HDTTs in the
final PPI4 data set is a measure of the po-
tential relevance of the network to dis-
ease. Additionally, we required that the
final interaction network PPI4 should
consist of >50% HDTTs. Through an ex-
haustive search procedure (as described
inMethods), we found that the combina-
tion of thresholds with P1 < 10
−4 (step I),
P2 < 10 × 10
−3 (step II), and P3 < 10
−6
(step III) produced the largest network
that fulfilled these requirements (Fig.
1A,B). In PPI4, seven of 13 (>50%) HTT-
associated proteins are known HDTTs.
This enrichment of a large number of
known HDTTs in PPI4 suggests that the
other proteins in the network are also rel-
evant to disease andmight influencemu-
tant HTT misfolding and aggregation in
model systems.
Figure 1. Predicting caudate nucleus-specific, dysregulated HTT-associated proteins by interaction
network filtering. (A) Data integration strategy for interaction network filtering by differentially ex-
pressed genes. By systematic integration (three filtering steps) of protein interaction and gene ex-
pression data (PPI1-3 and ΔEG1-3), a caudate nucleus-specific HD network (PPI4) with potentially
dysregulated, disease-relevant HTT-associated proteins was created. (B) Potential function of HTT-asso-
ciated proteins predicted though systematic HTT interaction network filtering. In PPI4, 13 potentially
dysregulated proteins are directly or indirectly linked to HTT. The orange ring indicates known
HD therapy targets (HDTTs). (C) Effects of the computationally predicted proteins CRMP1, KLF6,
HMGA1, and CFLAR on mutant HTT aggregation in cell-based assays. Potential modulator proteins
were coproduced as mCherry-tagged fusions with YFP-tagged HTTex1Q79 fusion protein in SH-EP
neuroblastoma cells. Formation of YFP-HTTex1Q79 aggregates was quantified after 48 h by high-con-
tent fluorescence imaging. Data are represented as mean ± SEM. (∗∗∗) P≤ 0.001, two-sided t-test with
unequal variance.
CRMP1 suppresses HTT misfolding and neurotoxicity
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A comparison of the performance of single- and multistep
interaction network filtering approaches
We utilized the manually curated set of HDTTs to examine the ef-
fect of the number of consecutive data integration steps on
the outcome of our network filtering procedure. First, the enrich-
ment of HDTTs in the interaction data sets (PPI1–PPI4) and the se-
lected gene expression data sets (ΔEG1, ΔEG2, and ΔEG3) was
determined (Fig. 1A; Supplemental Fig. S1A). HDTTsweremore en-
riched in the interaction network PPI1 compared to data sets of dif-
ferentially expressed genes. This provides evidence that focused
disease protein interaction networks contain relevant information
for disease research, in line with previous studies (Goehler et al.
2004). We also observed that procedures of one- or two-step inter-
action filtering only modestly increase the relative number of
HDTTs in the PPI2 and PPI3 networks. However, a large increase
was observed after three filtering steps (PPI4) (Supplemental Fig.
S1A), supporting our expectations that a three-step procedure is
most productive in identifying disease-relevant HTT-associated
proteins.
To further investigate whether all three filtering steps are
required to obtain maximum enrichment of HDTTs, we also fil-
tered the initial HTT network (PPI1) directly with a set of genes
that are differentially expressed in HD patients and healthy indi-
viduals (ΔEG3). This has been the computational approach most
commonly used to create disease-relevant interaction networks
(Chuang et al. 2007; Zhao et al. 2011). This procedure yielded
the interaction network PPID (Supplemental Fig. S1A; Supple-
mental Table S10A,B). Remarkably, the relative enrichment of
HDTTs in PPID (23% HDTTs) was considerably lower than in
PPI4 (54% HDTTs), supporting our view that the step-by-step inte-
gration of tissue expression data with PPI data helps in the identi-
fication of disease-relevant proteins (Fig. 1A; Supplemental Fig.
S1A). This difference was also observed when the significance
threshold was optimized independently for PPID (Supplemental
Fig. S1B). Thus, our studies indicate that consecutive filtering of
PPI data with multiple sets of differentially expressed genes is a
valuable approach to create focused, disease protein-centered in-
teraction networks.
Interaction network filtering reveals known dysregulated
HTT-associated proteins
Utilizing information available in the literature via PubMed, we
searched for descriptions of dysregulated HTT interacting proteins.
We found that the abundance of five HTT-associated proteins
(CASP6, PACSIN1, DNM1, SP1, and PRPF40A) in PPI4 is altered
in brains of HD patients or transgenic mice (Fig. 1B; Supplemental
Table S9). In addition, evidence was reported that the levels of
the proteins HMGB1 and HMGB2, which are close homologs
of HMGA1 (Fig. 1B), are reduced in HD cell lines (Qi et al. 2007).
These investigations support the assumption that systematic net-
work filtering is a useful approach to select dysregulated HTT-asso-
ciated proteins.
Previous studies indicate that alterations in gene transcrip-
tion, synaptic vesicle endocytosis, cytoskeletal reorganization,
apoptotic pathways, and RNAmetabolism are critical for the devel-
opment of HD (Truant et al. 2007; Caviston and Holzbaur 2009;
Fossale et al. 2011). Remarkably, all these processes can be associ-
ated with proteins in the derived PPI4 network. Thus, our system-
atic network filtering studies support these previous observations
(Fig. 1B), suggesting that abnormal interactions in these processes
contribute to pathogenesis.
Interaction network filtering enables the identification
of novel HTT aggregation modulators
We hypothesized that the network PPI4 should contain proteins
that influence polyQ-mediated HTT misfolding and aggregation
in model systems. To test this hypothesis, we focused on the
proteins KLF6, HMGA1, CFLAR, and CRMP1, which previously
have not been associated with HD pathogenesis (Fig. 1B). We co-
expressed the mCherry-tagged proteins KLF6, HMGA1, CFLAR,
and CRMP1 together with a YFP-tagged HTT exon-1 fragment
(YFP-HTTex1Q79) in SH-EP neuroblastoma cells and quantified
the formation of YFP-HTTex1Q79 aggregates through high-con-
tent fluorescence imaging (Abraham et al. 2004). We observed
that three of the four selected proteins (HMGA1, CFLAR, and
CRMP1) efficiently suppressed YFP-HTTex1Q79 aggregation in
SH-EP cells (Fig. 1C), supporting our assumption that aggregation
modulators are enriched by network filtering. A similar effect was
observed with a well-established suppressor of mutant HTT ag-
gregation DNAJB1 (Muchowski et al. 2000), which was used as a
positive control protein. The expression of YFP- and mCherry-
tagged proteins was confirmed by SDS-PAGE and immunoblotting
(Supplemental Fig. S1C,D). Thus, our cell-based studies suggest
that interaction network filtering with gene expression data and
the generation of disease protein-centered networks is a suitable
strategy to predict potential modulators of HTT misfolding and
aggregation.
For more detailed validation studies (see below), we focused
on the HTT interacting protein CRMP1, whose transcript in com-
parison to the other genes was found to be most significantly up-
regulated in brain compared to nonbrain tissues (P = 5.3 × 10−11).
This supports previous observations that CRMP1 is predominantly
expressed in neurons (Bretin et al. 2005), suggesting that abnormal
dysregulation of the protein in HD brains might contribute to the
neurodegenerative disease phenotype. A potential importance of
CRMP1 for neuronal function under physiological conditions
is also supported by gene knockdown studies in mice, indicating
that CRMP1 function is critical for learning and memory (Su
et al. 2007). Thus, for further more detailed experimental investi-
gations, we focused our efforts on the proteinCRMP1,which likely
is a neuron-specific modulator of mutant HTT misfolding and ag-
gregation in brains of HD patients.
CRMP1 expression levels are altered in brains
of HD transgenic mice
To investigate potential changes of CRMP1 protein levels in HD
animal models, we studied the expression of the protein in brains
of HD transgenic mice by SDS-PAGE and immunoblotting.
For detection, an antibody was applied that is specific to CRMP1
and does not recognize the related proteins DPYSL2, DPYSL3,
DPYSL4, and DPYSL5 (Supplemental Fig. S2A,B). First, striatal
tissues prepared from 12-mo-old YAC128 HD transgenic mice
that express a full-length human HTT protein with an expanded
polyQ tract of 128 glutamines were examined (Slow et al.
2003). We found that levels of CRMP1 protein were significantly
reduced in brains of HD transgenicmice compared to age-matched
controls (Fig. 2A,B). Next, the expression of CRMP1 was assessed
in R6/2 HD transgenic mice, which produce a truncated HTT
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exon-1 fragment with a pathogenic polyQ tract of ∼150–200 glu-
tamines (Mangiarini et al. 1996). Protein lysates were prepared
from 4-, 8-, and 14-wk-old R6/2 transgenic mouse brains and
wild-type controls and analyzed by SDS-PAGE and immunoblot-
ting. In 14-wk-old transgenic R6/2 mice, which show a severe dis-
ease phenotype (Labbadia et al. 2011), levels of CRMP1 were
significantly reduced compared to age-matched controls (Fig. 2C,
D), consistent with the results from the YAC128 HD model
(Fig. 2A,B). The reduced CRMP1 protein levels in R6/2 mice also
correspond to decreased Crmp1 transcript levels in brains of 12-
wk-old R6/2mice compared to age-matched controls (Supplemen-
tal Fig. S2C).
Interestingly, we found that CRMP1 levels were enhanced in
4-wk-old presymptomatic R6/2 transgenic mice, which suggests
that protein levels are up-regulated during early stages of patho-
genesis (Fig. 2C,D). Increased CRMP1 levels at early disease stages
suggest that stress conditions may induce the expression of the
protein. To address this question, we analyzed the promoter region
of theCRMP1 gene (600 bp) for potential transcription factor bind-
ing sites (Supplemental Fig. S2D; Supplemental Table S11). We
observed multiple conserved heat shock factor (HSF1/HSF2) bind-
ing sites in the cis-regulatory region upstream of the transcription-
al start site, suggesting that CRMP1 gene transcription is heat
shock inducible. We next tested this hypothesis using a SH-SY5Y
neuroblastoma cell line (Fig. 2E–G). Cells grown at 37°Cwere incu-
bated for 30min at 45°C, and then analyzed by SDS-PAGE and im-
munoblotting. We found that CRMP1 protein levels are increased
at 45°C (Fig. 2E,F). Similar results were obtained for the well-
known heat shock-inducible protein HSPA1A (positive control).
The findings were confirmed by immunofluorescence microscopy
studies (Fig. 2G), indicating that CRMP1,
similar to HSPA1A, is a heat-inducible
stress protein.
Altered CRMP1 levels affect HTT
aggregation and toxicity in a PC12
cell model
To investigate whether CRMP1 influenc-
es the aggregation and toxicity ofmutant
HTT in mammalian cells, we increased
or reduced the protein’s abundance in
a PC12 HD cell model overproducing
a pathogenic HTTQ103-EGFP fusion pro-
tein (Apostol et al. 2006). Cells were treat-
ed with CRMP1 siRNA, and HTTQ103-
EGFP aggregation was analyzed after
40 h using the filter retardation assay
(Wanker et al. 1999). To quantify
HTTQ103-EGFP-induced cellular toxici-
ty, we used a caspase 3/7 assay. Finally,
CRMP1 and HTTQ103-EGFP protein lev-
els were examined by SDS-PAGE and im-
munoblotting. We observed that siRNA-
mediated reduction of CRMP1 protein
levels increased both the aggregation
and toxicity of HTTQ103-EGFP in PC12
cells (Fig. 3A–D). In contrast, a signifi-
cant reduction of both HTTQ103-EGFP
aggregation and toxicity was detected
in cells overproducing a hemagglutinin
(HA)-tagged CRMP1 fusion protein (Fig.
3E–H), confirming our observations from neuroblastoma cells
(Fig. 1C).
Overproduction of CRMP1 reduces toxicity and aggregation
of mutant HTT in HD transgenic flies
Next, we examined whether CRMP1 influences HTT-mediated
neurotoxicity in a Drosophila model of HD (Kaltenbach et al.
2007). In this model, an N-terminal HTT fragment with a patho-
genic polyQ tract of 128 glutamines (HTT336Q128) is overpro-
duced in photoreceptor neurons. We found that coproduction of
humanCRMP1 and itsDrosophila homolog CRMP significantly re-
duced HTT336Q128-induced photoreceptor degeneration in HD
transgenic flies (Fig. 4A–G), supporting results from the cell-based
assays (Figs. 1C, 3H). In contrast, the control protein GFP had no
effect on photoreceptor damage (Fig. 4D,G). The production of
HTT336Q128 and CRMP1 in Drosophila eye imaginal discs was
confirmed by immunoblotting and immunofluorescence micros-
copy (Supplemental Fig. S3A–F).
In order to investigate whether CRMP1 influences motor
function, we examined the climbing ability of HD transgenic flies.
We discovered that HD transgenic flies display an impairment of
motor activity compared to wild-type controls. Climbing was sig-
nificantly improved in CRMP1-overproducingHD transgenic flies,
whereas the control protein GFP showed no effect (Fig. 4H).
Hence, our climbing studies with HD transgenic flies further sup-
port a protective function of CRMP1 in neuronal cells.
Next, we used immunofluorescence microscopy (IFM) to as-
sess whether CRMP1 colocalizes with insoluble HTT336Q128
aggregates in HD transgenic flies. Analysis of eye imaginal discs
Figure 2. Expression of CRMP1 in brains of HD transgenic mice and cell models. (A) Endogenous
CRMP1 protein levels are reduced in brain tissues of 12-mo-old YAC128 HD transgenic mice compared
to controls. Protein extracts prepared from striatal tissues of wild-type and transgenic HD mice were an-
alyzed by SDS-PAGE and immunoblotting using the anti-CRMP1 antibody 504-518. (B) Quantification of
∼65 kDaCRMP1 bands in A. Values represent themeans of three independent experiments. (∗∗) P≤ 0.01,
two-sided t-test with unequal variance. (C) Endogenous CRMP1 levels are altered in brains of R6/2 HD
transgenicmice compared to controls. Protein extracts were analyzed by SDS-PAGE and immunoblotting
using the anti-CRMP1 antibody 504-518. (D) Quantification of CRMP1 protein bands shown in C. Values
represent the means of three independent experiments. (∗) P < 0.1; (∗∗) P≤ 0.01, two-sided t-test with
unequal variance. (E) Heat stress induces endogenous CRMP1 protein levels in SH-SY5Y neuroblastoma
cells. Cell lysates were analyzed by SDS-PAGE and immunoblotting. (F) Quantification of CRMP1 and
HSPA1A protein bands shown in E. Values represent the means of three independent experiments. (∗∗)
P≤ 0.01, two-sided t-test with unequal variance. (G) Analysis of CRMP1 and HSPA1A protein expression
in SH-SY5Y cells under heat stress conditions by immunofluorescence microscopy. Data in B, D, and F are
represented as mean ± SEM.
CRMP1 suppresses HTT misfolding and neurotoxicity
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of late third instar larvae revealed colocalization of CRMP1
with HTT336Q128 in inclusion bodies (Fig. 4I), indicating that
CRMP1 is recruited to insoluble HTT aggregates in HD transgenic
flies. A similar result was obtained from brains of HD transgenic
mice expressing an N-terminal, aggregation-prone HTT fragment
(Supplemental Fig. S3G), supporting the results from the Droso-
phila experiments.
Finally, we examined whether overproduction of CRMP1
influences the formation of insoluble HTT336Q128 aggregates
in photoreceptor neurons. An IFM analysis of eye imaginal discs
of late third instar larvae demonstrated that HD flies that over-
produce human CRMP1 or its Drosophila homolog CRMP exhibit
significantly lower numbers of HTT336Q128 inclusion bodies
compared to control flies (Fig. 4J,K), confirming the results ob-
tained in neuroblastoma and PC12 cells (Figs. 1C, 3F,G).
The missense mutation D408V suppresses the effect of CRMP1
on mutant HTT aggregation and toxicity in model systems
Previous studies in Drosophila indicate that an exchange of an as-
partic acid at position 430 for a valine residue alters the function
of CRMP (Rawls 2006), suggesting that exchanging the corre-
sponding amino acid in human CRMP1 might also influence
its function. We found that the aspartic acid at position 408 is
highly conserved in human CRMP1 (Fig. 5A). Subsequently, we
engineered the humanproteinCRMP1-D408V for functional stud-
ies in cell model systems. We coproduced mCherry-tagged fusion
proteins (for example mCherry-CRMP1-D408V) together with
YFP-HTTex1Q79 in SH-EP neuroblastoma cells and systematically
examined the formation of insoluble YFP-HTTex1Q79 aggregates.
Protein aggregates were quantified after 48 h by measuring YFP
fluorescence in intracellular inclusion bodies using a high-content
fluorescence imaging technology. We found that coproduction of
wild-typeCRMP1 efficiently reduced YFP-HTTex1Q79 aggregation
in SH-EP cells (Fig. 5B). In contrast, the mutant protein CRMP1-
D408V behaved like the control protein luciferase and did not
reduce YFP-HTTex1Q79 aggregation. A reduction of YFP-
HTTex1Q79 aggregation was also observed in conjunction with
the molecular chaperone DNAJB6, whereas the control protein
GIT1 showed the opposite effect, confirming previously published
results (Goehler et al. 2004; Hageman et al. 2010).
To examine whether protein expression levels influence the
effects on YFP-HTTex1Q79 aggregation, we quantified mCherry-
and YFP-tagged fusion proteins in transiently transfected SH-EP
cells. We obtained similar ratios for all mCherry- and YFP-tagged
fusion proteins in cotransfected cells (Supplemental Fig. S4A), in-
dicating that the CRMP1-mediated reduction of HTT aggregation
cannot be explained by a simple protein dosage effect.
Next, we studiedwhether imaging of YFP fluorescence indeed
is suitable to detect insoluble YFP-HTTex1Q79 aggregates in SH-EP
cells. We performed additional imaging studies utilizing the
monoclonal antibody MW8 to detect YFP-HTTex1Q79 inclusion
bodies. This antibody preferentially recognizes insoluble HTT pro-
tein aggregates in cells but not monomers or small oligomers
(Ko et al. 2001). The quantification of YFP fluorescence and
MW8 immunoreactivity yielded very similar results (Fig. 5B), con-
firming that insoluble YFP-HTTex1Q79 aggregates are detected by
YFP imaging.
Finally, we investigated whether CRMP1-D408V influences
mutant HTT-induced photoreceptor degeneration in the Droso-
phila HD model. We found that the mutant protein, like the con-
trol GFP, did not rescue photoreceptor degeneration in Drosophila
eyes (Fig. 5C; Supplemental Fig. S4B), whereas the wild-type
CRMP1 protein did (Fig. 4E,G). Thus, our studies with cell models
and HD transgenic flies indicate that the missense mutation
D408V in CRMP1 is sufficient to suppress its effect on mutant
HTT aggregation and toxicity.
CRMP1 reduces the aggregation of ATXN1 and TARDBP
in cell-based assays
We hypothesized that CRMP1 might display properties similar to
molecular chaperones such as HSPA1A or crystallins (Morimoto
2008; Robertson et al. 2010), which target several neurodegenera-
tive disease proteins and suppress their aggregation propensity.
To address this question, we examined the effect of CRMP1
on the disease proteins ATXN1Q82 (a toxic polyQ-expanded
ATXN1) and TARDBP, which form insoluble protein aggregates
in patients with spinocerebellar ataxia type 1 (SCA1) and fronto-
temporal dementia, respectively (Neumann et al. 2006). YFP-
tagged ATXN1Q82 or TARDBP fusion proteins were coproduced
with mCherry-tagged CRMP1 in SH-EP cells. After 48 h, the for-
mation of insoluble protein aggregates was quantified using
high-content fluorescence imaging (Fig. 5D,E). We observed that
wild-type CRMP1 potently reduces the aggregation of both YFP-
ATXN1Q82 andYFP-TARDBP in cell-based assays,whereas themu-
tant protein CRMP1-D408V did not exert this effect (Fig. 5D,E).
Reduction in aggregation of YFP-ATXN1Q82 and YFP-TARDBP
was also detected with the molecular chaperone DNAJB1, which
was used as a positive control. Protein expression was verified
by SDS-PAGE and immunoblotting (Supplemental Fig. S4C,D).
Figure 3. CRMP1 protein production influences polyQ-mediated HTT
aggregation and toxicity in PC12 cells. (A,E) SDS-PAGE and immunoblot
analysis of PC12 cells overproducing HTTQ103-EGFP fusion protein.
Cells treated with si-CRMP1 RNA (A) or overproducing a HA-tagged
CRMP1 protein (E) were analyzed. (B,F) Detection of insoluble
HTTQ103-EGFP aggregates in si-CRMP1-treated (B) and HA-CRMP1 over-
producing (F ) PC12 cells. Insoluble aggregates (black dots) were detected
by filter retardation assay. (C,G) Quantification of insoluble HTTQ103-
EGFP aggregates shown in B and F by image analysis: n = 3; (∗∗∗) P≤
0.001, two-sided t-test. (D,H) Quantification of caspase-3/7 activity in si-
CRMP1-treated (D) and HA-CRMP1 overproducing (H) PC12-HTTQ103-
EGFP cells: n = 3; (∗∗∗) P≤ 0.001, two-sided t-test. Data in C, D, G, and H
are represented as mean ± SEM.
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Thus, our cell-based studies suggest that CRMP1 functions as a
stress-inducible molecular chaperone in neuronal cells.
CRMP1 directly targets mutant HTT fragments and reduces
their spontaneous self-assembly in cell-free assays
We also investigated whether CRMP1 directly influences polyQ-
mediated HTT aggregation in cell-free assays. GST- and His-tagged
fusion proteins (GST-HTTex1Q49, His-CRMP1, and His-CRMP1-
D408V) were produced in E. coli and purified to >90% homogene-
ity by affinity chromatography (Fig. 6A). Soluble GST-HTTex1Q49
fusion proteinwas incubatedwith PreScission protease (PP) and ei-
ther His-CRMP1 or His-CRMP1-D408V.We quantified the sponta-
neous formation of insoluble HTTex1Q49 aggregates over time
using the filter retardation assay (Wanker et al. 1999). PP was add-
ed to reactions to remove the GST-tag from the GST-HTTex1Q49
fusion protein and to initiate spontaneous HTTex1Q49 ag-
gregation (Supplemental Fig. S5A). We found that spontaneous
HTTex1Q49 aggregation was slowed down through addition of
wild-type His-CRMP1, whereas the mutant protein His-CRMP1-
D408Vhad no effect (Fig. 6B). A reduction of HTTex1Q49 aggrega-
tion was also observed with the molecular chaperone HSPA1A,
confirming previously published results (Muchowski et al. 2000).
Next, we studied whether the soluble HTTex1Q49 protein is a
direct target of CRMP1 in cell-free aggregation assays. To detect
soluble HTTex1Q49 molecules we used the monoclonal antibody
3B5H10, which exclusively recognizes expanded polyQ tracts in
soluble HTT molecules (Miller et al. 2011). An analysis of time-re-
solved HTTex1Q49 aggregation assays with dot-blot assays re-
vealed that soluble 3B5H10-reactive HTT molecules disappeared
at a slower rate in the presence of wild-type CRMP1 than in the
presence of mutant CRMP1-D408V (Fig. 6C). A similar effect
was observed with the molecular chaperone HSPA1A, which
directly targets soluble, aggregation-prone HTT molecules and re-
duces their aggregation propensity (Muchowski et al. 2000).
Thus, it can be concluded that CRMP1 directly targets soluble
HTTex1Q49molecules with exposed polyQ sequences and reduces
their propensity to spontaneously convert into insoluble protein
aggregates.
Figure 4. CRMP1 overproduction mitigates mutant HTT-induced pho-
toreceptor degeneration and motor impairment in HD transgenic flies.
(A–F ) Investigation of eye sections. Analysis of eye sections in control flies
(A) and transgenic flies overproducing CRMP1 (B) or HTT336Q128 (C )
alone. Coproduction of the control protein GFP does not influence
HTT336Q128-induced retina degeneration (D), whereas coproduction
of human CRMP1 (E) or Drosophila CRMP (F) mitigates HTT336Q128-in-
duced retinal degeneration. Arrows indicate retinal degeneration. (G)
Quantification of retinal degeneration in control and HD transgenic flies
(A–F ): n≥ 9 flies per genotype; (∗∗∗) P≤ 0.001, two-sided t-test with
unequal variance. (H) CRMP1 significantly improves climbing abilities of
HTT336Q128 overproducing HD transgenic flies. Data were analyzed
using Graphpad Prism 5: n≥ 16 flies per genotype; P = 0.0017; linear re-
gression followed by F-test. (I–J) Immunofluorescence analysis of eye
imaginal discs of HD transgenic flies. (I) MYC-CRMP1 colocalizes with
HTT336Q128 in multiple inclusion bodies with a diameter of 0.2–0.4
μm. (J) In contrast to the control protein GFP, coproduction of the proteins
CRMP1 and CRMP reduced both the number as well as the average size
of HTT336Q128 inclusion bodies. (K) Quantification of the number of
HTT336Q128 inclusion bodies in HD flies coproducing modulator
proteins. An area of 35.71 μm2 in the middle of the posterior third of
eye imaginal discs was systematically analyzed: n≥ 5; (∗∗∗) P≤ 0.001,
two-sided t-test with unequal variance. Data inG, H, and K are represented
as mean ± SEM.
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Previous studies indicate that functional high molecular
weight CRMP1 oligomers are formed under nondenaturating con-
ditions (Deo et al. 2004). This suggests that a change in the struc-
ture or stability of CRMP1 oligomers through the missense
mutation D408V could be responsible for the reduced activity of
CRMP1 on HTT aggregation (Fig. 6B).
This view is supported by our compu-
tational structure analysis of mouse
CRMP1, which suggests that aspartic
acid D408 is critical for oligomer assem-
bly and stability (Supplemental Fig.
S5B,C). In order to address whether the
mutation D408V influences the stability
of CRMP1 oligomers, the recombinant
proteins His-CRMP1 and His-CRMP1-
D408V were incubated with different
concentrations of urea and analyzed by
blue-native (BN) PAGE and immunoblot-
ting. We observed that both wild-type
and mutant CRMP1 form tetramers un-
der nondenaturating conditions, migrat-
ing at∼480 kDa (Supplemental Fig. S5D).
This confirms previously published re-
sults, indicating that CRMP1 proteins
form stable oligomers (Deo et al. 2004).
Interestingly, analysis by BN-PAGE re-
vealed that wild-type CRMP1 oligomers
are less stable and dissociated with
lower urea concentrations than mutant
CRMP1-D408V oligomers (Supplemen-
tal Fig. S5D). This suggests that increased
oligomer stability might be responsible
for the reduced activity of the CRMP1-
D408V protein in HTT aggregation as-
says. This result is supported by previous-
ly published studies indicating that
flexibility and reorientation of domains
in chaperones are critical for their func-
tion (Haslbeck et al. 2004; White et al.
2006; Quan et al. 2014). Analysis by
SDS-PAGE and Coomassie staining con-
firmed that similar amounts of both
proteins were analyzed (Supplemental
Fig. S5E). Finally, we also observed a
difference between the proteins His-
CRMP1 and His-CRMP1-D408V when
they were examined for their intrinsic
tryptophan fluorescence (Supplemental
Fig. S5F). Recent studies indicate that
oligomerization and aggregation of pro-
teins is associated with an increase of in-
trinsic protein fluorescence (Chan et al.
2014), supporting our results by BN-
PAGE that CRMP1-D408V but not the
wild-type protein forms higher molecu-
lar weight oligomers (HMWOs) (Supple-
mental Fig. S5D). Thus, our biochemical
and biophysical studies suggest that the
mutation D408V alters the stability
CRMP1oligomers and promotes their ab-
normal oligomerization.
Discussion
This study reports the development and application of a computa-
tional approach utilizing protein–protein interaction and gene ex-
pression data to identify disease-relevant proteins that are
Figure 5. A mutant variant of CRMP1 (D408V) shows impaired activity in cell-based assays and HD
transgenic flies. (A) Multiple sequence alignment of CRMP1 protein sequences. The aspartic acid residue
408 in human CRMP1 is conserved in a large number of related proteins (yellow box). (B) Effects of
mCherry-tagged CRMP1 and CRMP1-D408V fusion proteins on aggregation of YFP-tagged
HTTex1Q79 in cell-based assays. Formation of insoluble YFP-HTTex1Q79 aggregates in SH-EP cells
was quantified by high-content fluorescence imaging. Aggregates were detected by YFP fluorescence
of HTT aggregates or by immunostaining using the anti-HTT antibody MW8. MW8 preferentially detects
insoluble HTT aggregates. Data are represented asmean ± SEM. (∗∗∗) P≤ 0.001, two-sided t-test with un-
equal variance. (C) Retinal degeneration in control flies carrying the GMR-GAL4 driver (GMR) alone and
in flies coexpressing HTT336Q128 with CRMP1-D408V or the GFP control protein under control of the
GMR driver. Analysis of eye sections reveals that in contrast to wild-type CRMP1, neither GFP nor CRMP1-
D408V affects HTT336Q128-induced retinal degeneration compared to the GMR flies. (D–E) Effects of
mCherry-tagged CRMP1 or CRMP1-D408V on aggregation of YFP-tagged ATXN1Q82 (D) or TARDBP
(E) in cell-based assays. (D) YFP-ATXN1Q82 or (E) YFP-TARDBP aggregates were detected in SH-EP cells
by YFP fluorescence and quantified by high-content fluorescence imaging. Data are represented asmean
± SEM. (∗∗∗) P≤ 0.001, two-sided t-test with unequal variance.
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associated with HTT and influence its aggregation propensity. The
methodwas designed to select proteins that are dysregulated in the
caudate nucleus in HD brains from a large, HTT-centered PPI data
set. The caudate nucleus displays severe neuropathological chang-
es at an early stage of disease, suggesting that it plays a critical role
in the development and progression of HD (Aylward 2007). Our
protein interaction network filtering approach greatly reduced
the complexity of the initially very large HTT-centered PPI net-
work in a stepwise manner. For filtering of PPI data, we used infor-
mation on genes that are differentially expressed in (1) brain
compared to nonbrain tissues; (2) caudate nucleus compared to
other brain tissues; and (3) brains of HD patients compared to
healthy individuals. This finally resulted in the generation of a
focused network with potentially dysregulated HTT-associated
proteins (PPI4) that might influence HTT misfolding and aggrega-
tion in neurons.
We designed our protein interaction network filtering proce-
dure to create a focused HTT interaction network that contains a
high percentage of already known HD therapy targets (HDTTs).
These targetswere shown in previous studies to influence the path-
ogenesis in various HD model systems (Kalathur et al. 2012), sug-
gesting that the other proteins in the network PPI4 (Fig. 1B) might
also affect the disease process in HD. Through our network filter-
ing approach, four proteins (HMGA1, KLF6, CFLAR, and CRMP1)
were selected that have not previously been linked to HD patho-
genesis. They subsequently were systematically examined in cell-
based assays to determine whether they influencemutant HTT ag-
gregation. Strikingly, we found that three (HMGA1, CFLAR, and
CRMP1) of four computationally predicted proteins are potent
modulators of mutant HTT aggregation (Fig. 1C), supporting our
initial hypothesis that among dysregulated HTT interaction part-
ners, aggregation modulators can be identified. Intriguingly, two
of them are located in chromosomal regions (CFLAR: 2q33;
CRMP1: 4p16), which harbor genes that potentially influence
HD age of onset (Kalathur et al. 2012), suggesting that they are can-
didates for genetic modifiers.
Formore detailed experimental validation studies, we focused
our efforts on the protein CRMP1, whose transcript levels are sig-
nificantly diminished in HD brains (Fig. 1B). CRMP1 is a cytoplas-
mic phosphoprotein that is predominantly expressed in neurons
(Goshima et al. 1995). Previous studies revealed that mice lacking
CRMP1 show impairment of learning andmemory (Su et al. 2007),
suggesting that a reduction of CRMP1 levels in HD brains might
contribute to the disease phenotype (Paulsen et al. 2013). This
view is also supported by studies in cell model systems, indicating
that reduced levels of CRMP1 promote
death of spinal cord neurons (Kurnellas
et al. 2010). Therefore, previously pub-
lished studies support the selection of
CRMP1 for more detailed experimental
validation studies in HD model systems.
Our studies with cell-based assays
and HD transgenic flies revealed that
CRMP1 influences both aggregation
and toxicity of mutant HTT inmammali-
an cells (Figs. 3, 4). While overproduc-
tion of CRMP1 significantly decreased
misfolding and toxicity of mutant HTT,
down-regulating the protein levels
through siRNA treatment showed the op-
posite effect. Together, these results sug-
gest that in neurons with high levels of
CRMP1, abnormalmutantHTT aggregation is suppressed; whereas
in neurons with low CRMP1 protein levels, the protein forms in-
soluble aggregates. Intriguingly, we noted that the expression of
CRMP1 is significantly lower in the caudate nucleus compared to
other brain regions (P = 4.7 ∗ 10−28)—an observation which could
help to explain the region specific vulnerability in HD brains.
Currently, the molecular mechanisms that lead to a decrease
of CRMP1 protein levels in brains of HD patients and transgenic
mice (Fig. 2A–D) are unclear. Experimental evidence indicates
that pathogenesis in HD is associated with altered gene expression
in patient brains (Cha 2000; Ross and Thompson 2006), suggest-
ing that reduced gene transcription could be responsible for the
decrease of CRMP1protein. This is also supported by the reduction
of Crmp1 transcript levels in transgenic HD mice (Supplemental
Fig. S2C). However, a reduction of CRMP1 protein levels could
also be caused by the recruitment of the protein into insoluble
HTT inclusion bodies (Fig. 4I; Supplemental Fig. S3G), enhanced
aggregation in response to cellular stress (Meriin et al. 2001;
Hipp et al. 2014), or enhanced protein degradation duringHD pro-
gression. Additional studies will be necessary to address this ques-
tion in more detail.
Our experiments with cell-free assays indicate that CRMP1
directly targets soluble, aggregation-prone HTT molecules and re-
duces their propensity to spontaneously self-assemble into insolu-
ble, amyloidogenic protein structures (Fig. 6B,C). This suggests
that CRMP1 acts as a molecular chaperone, which directly binds
to unfolded or partially folded aggregation-pone proteins. Molec-
ular chaperones are classified either as “foldases” or “holdases.”Al-
though foldases (e.g., HSPA1A and DNAJB1) promote correct
folding in an ATP-dependent process, holdases prevent the aggre-
gation of misfolded proteins in an ATP-independent manner
(Haslbeck et al. 2005). Our studies indicate that CRMP1 functions
as a holdase that does not require ATP hydrolysis to suppress
mutant HTT aggregation (Figs. 2E–G, 5B,C, 6B,C). This is also
supported by preliminary studies indicating that CRMP1, in
contrast to HSPA1A, is unable to refold denatured luciferase in
cell-based assays. We propose a model in which a CRMP1 protein
with high flexibility directly binds soluble, unfolded, aggregation-
prone polyQ-containing HTT molecules and stabilizes their ag-
gregation-incompetent conformation (Kim et al. 2009). This ef-
fect, however, is diminished when CRMP1 harbors the mutation
D408V, which enhances oligomer stability in vitro (Supplemental
Fig. S5D). Previous studies indicate that flexibility of oligomers
and reorganization of domains are critical for chaperone activity.
Hsp26, a heat-sensitive small heat shock protein, e.g., forms
Figure 6. A mutant variant of CRMP1 (D408V) shows impaired activity in cell-free HTT aggregation
assays. (A) The proteins His-CRMP1 and His-CRMP1-D408V were produced in E. coli and purified to
>90% homogeneity by affinity chromatography. Protein expression and purity was confirmed by
Coomassie staining of SDS gels or immunoblotting (IB). (B) Analysis of spontaneous HTTQ49 aggrega-
tion in the presence of modulator proteins in cell-free assays by filter retardation assay. SDS-insoluble
HTTQ49 protein aggregates were detected on filter membranes using the anti-HTT antibody
CAG53b. Representative results from three independent experiments are shown. (C) Analysis of sponta-
neous HTTQ49 aggregation in the presence of modulator proteins by dot-blot assays. The conversion of
soluble HTTQ49 into insoluble protein aggregates was monitored using the antibody 3B5H10.
Representative results from three independent experiments are shown.
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nonfunctional oligomers under normal physiological conditions,
but can undergo structural rearrangements at higher temperatures
to facilitate the formation of functional oligomers with chaperone
activity. This includes the dissociation of larger oligomers into
dimers, which is required for the efficient interaction with non-
native proteins (Haslbeck et al. 2004; White et al. 2006). Further-
more, it was demonstrated that the protein Spy for high
chaperone activity requires a high oligomer flexibility (Quan
et al. 2014). A chaperone function of CRMP1 is also supported
by our observation that it reduces the spontaneous aggregation
of the disease proteins ATXN1 and TARDBP in cell-based assays
(Fig. 5D,E). Thus, we suggest that CRMP1 can function under
physiological conditions as a neuron-specific molecular chaper-
one that directly binds to unfolded, aggregation-prone proteins
and prevents their abnormal deposition into insoluble inclusion
bodies.
In conclusion, we propose that step-by-step filtering of pro-
tein interaction networks with differentially expressed genes is a
powerful strategy to identify novel proteins that control misfold-
ing and proteotoxicity of mutant HTT. The approach is scalable
and can be expanded to include additional data types. More im-
portantly, it can be applied to other aggregation-prone disease pro-
teins, given that high-quality PPI and gene expression data from
affected tissues of patients and healthy individuals are available.
The efficiencyof our filtering strategy is underscored by the discov-
ery of the neuron-specific protein CRMP1, which functions as a
potent suppressor of HTT aggregation and toxicity in various in vi-
tro and in vivo disease model systems.
Methods
Data sets
Protein interaction data were extracted from the UniHI database
(http://www.unihi.org/). For theHDnetwork, data froma previous
Y2H-screen for HTT interactors were additionally included (Goeh-
ler et al. 2004). Gene expression data sets utilized for filtering
of protein interaction networks can be found in Supplemental
Table S1. Manually annotated HD therapy targets (HDTTs) were
obtained from the curators of the HD Research Crossroads data-
base. This database provides themost comprehensive collection of
potential therapeutic molecular targets for HD to date (Kalathur
et al. 2012).
Analysis of gene expression data
For detection of differentially expressed genes in brain versus non-
brain tissues (ΔEG1), gene expression data of normal tissues were
obtained from the SymAtlas database (http://biogps.org) (see also
Supplemental Table S1). Statistical significance of differential ex-
pression was determined using a local pooled error approach
(Jain et al. 2003). Derived P-values were corrected for multiple
comparisons using the Benjamini-Hochberg procedure (Benja-
mini and Hochberg 1995).
For the generation of networks that are specific to the caudate
nucleus expression profiles obtained from normal tissue, samples
of different brain regions were compared (Hodges et al. 2006).
Similarly, samples fromHD patients compared to healthy individ-
uals were used to derive disease specificity. The significance of dif-
ferential gene expression was assessed using a linear model, as it
allowed the correction for collection sites, gender, and age in the
case of the HD study (Smyth 2004; Hodges et al. 2006). P-values
were subsequently adjusted by applying the Benjamini-Hochberg
procedure (Benjamini and Hochberg 1995).
Optimization of selection thresholds for the generation
of the dysregulated HTT network PPI4
For optimization of thresholds P1, P2, and P3, a curated list of
HDTTs was used. In this list, each HDTT is assigned with a target
validation score ranging from0 to 5 describing the status of the ex-
perimental validation of its disease-modifying effects. The highest
score of 5.0 is assigned if a drug or a gene therapy targeting the
gene has shown efficacy in a Phase 3 clinical trial, whereas a score
of 4 states that an improvement of theHD phenotype has been ob-
served in rodent models upon targeting a gene by drugs or genetic
intervention. A score of 3 is assigned to genes and proteins where
a causal relationship with HD was observed in a validated cell
culture or lower organismmodel of HDupon genetic or pharmaco-
logic modification. Lower scores are assigned if genes show altered
functional activity in HD, changes in expression, binding to HTT,
or are linked to HD-relevant biological processes. To ensure that
the set of HDTTs constitutes a truly independent set, i.e., is not bi-
ased toward HTT interactors or differentially expressed genes in
HD, we required that HDTTs have score values equal to or larger
than 3. Thus, information about huntingtin interaction partners
or gene expression changes in tissues of HD patients was not uti-
lized for the definition of HDTTs. Altogether, a set of 476 unique
HDTTs passed this requirement.
To determine an optimal set of significance thresholds, the
network filtering strategy was repeatedly applied to the PPI net-
works. Thresholds for detection of differentially expressed genes
(P1, P2, and P3) were independently varied using a range of values
between 5 × 10−8 and 1 × 10−2. All possible combinations of these
thresholds were evaluated, and the relative number of HDTTs
as well as the total number of proteins in the final PPI4 data set
was recorded after iterative network filtering. In total, 2197 ( =
133) combinations of threshold values were tested to optimize
the relative percentage of included HDTTs in the final network
(PPI4). We demanded that the precision or positive predictive val-
ue [PPV = (TP− 1)/(P− 1), in which TP is the number of HDTTs,
and P is the total number of proteins included in the network]
is larger than 0.5. The factor (−1) is to exclude HTT from the calcu-
lation. The thresholds with P1 = 10
−4 for the first (ΔEG1), P2 = 10
−3
for the second (ΔEG2), and P3 = 10
−6 for the third filtering step
(ΔEG3) were selected as optimal, since they resulted in the highest
relative number of HDTTs in PPI4 with a PPV > 0.5.
Other statistical methods
Experimental data in most experiments were analyzed with two-
sided t-tests; details can be found in the figure legends. Additional-
ly, we applied linear regression followed by an F-test to analyze
whether CRMP1 significantly improves motor dysfunction in
HTT336Q128 transgenic flies.
Analysis of cis-regulatory sequences of CRMP1
We used the sequence NM_001313 and exon 1 to define the tran-
scriptional start site of the gene encoding CRMP1. Subsequently
the ConTra v2 software (Broos et al. 2011) was applied to identify
potential heat shock factor (HSF) binding sites. Default software
parameters were used for the analyses. Position weight matrices
were obtained from the TRANSFAC database (version 10.4). Indi-
vidual HSF binding sites are described in Supplemental Table S11.
Plasmids
The destination plasmids pGEX-6p-D21, pQLinkHD, pTLHA1-D-
48, pmCherryGW, pTHW, and pTMWwere utilized for the expres-
sion of recombinant proteins in E. coli, mammalian cells, and flies.
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cDNAs were shuttled into destination plasmids using the Gateway
technology (Invitrogen). Entry plasmids harboring the genes en-
coding the proteins CRMP1, CRMP1-D408V, DPYSL2, DPYSL3,
DPYSL4, DPYSL5, DNAJB1, HSPA1A, or luciferase were utilized.
For high-content fluorescence imaging experiments, a cDNA frag-
ment encoding HTTex1Q79 was cloned into the expression vector
pdEYFP-C1Amp (Imagenes). P{EPgy2} (Kalathur et al. 2012) was
used in Drosophila for overexpression of endogenous CRMP. The
plasmid for expression of HTT336Q128 in Drosophila was de-
scribed previously (Kaltenbach et al. 2007).
Antibodies
Polyclonal rabbit anti-CRMP1 antibodies were generated using the
KLH-MBS-conjugated linear peptides 504-YEVPATPKYATPAPS-
518 and 513-ATPAPSAKSSPSKHQ-527 (Eurogentec). The antibod-
ies were affinity purified on an AF-Amino-TOYOPEARL 650M (1
mL) column, containing ACH sepharose (0.375 g) and CNBR-acti-
vated sepharose (0.375 g) by Eurogentec. HTT aggregates were de-
tected by monitoring YFP fluorescence as well as MW8 antibody
immunoreactivity. A complete list of the antibodies used can be
found in Supplemental Table S12.
Silencing and overexpression of CRMP1 in PC12 cells
For CRMP1 silencing, PC12 cells (Apostol et al. 2006) were trans-
fected (Lipofectamine 2000) with 50 pmol CRMP1-specific siRNA
or 50 pmol nontargeting siRNA (On-target Plus smart pool
L-090088, On-target plus siCONTROL D-001810; Dharmacon,
Inc.). For CRMP1 overproduction, PC12 cells were transfected
with the plasmid pTLHA1-D-CRMP1 encoding a HA-tagged
CRMP1 protein and with the empty control plasmid pTLHA1-D-
48. In CRMP1 knockdown and overexpression experiments,
HTTQ103-EGFP expression was induced 12 h post-transfection
with 5 µM ponasterone A (PonA). HTTQ103-EGFP aggregates
were quantified using a filter retardation assay (Wanker et al.
1999) and a LAS-3000 imaging system (Fujifilm). Cellular toxicity
was analyzed using the Apo-ONE homogenous caspase 3/7 assay
(Promega).
Effect of heat stress on CRMP1 and HSPA1A protein
expression in SH-SY5Y cells
SH-SY5Y cells were seeded on coverslips in 24-well cell culture
plates for immunofluorescence microscopy studies (50,000 cells/
well). For SDS-PAGE and immunoblotting, SH-SY5Y cells were
seeded in 5-cm cell culture petri dishes (1 billion cells/well).
After 24 h, cell culturemediawere exchangedwith prewarmedme-
dia at 45°C or 37°C. After 30 min incubation at 45°C or 37°C, me-
diawere exchanged, and cells were incubated for another 4 h at 37°
C. Endogenous protein levels were examined by confocal micros-
copy and immunoblotting. For confocal microscopy, cells were
fixed in 4% paraformaldehyde, washed with PBS, permeabilized
for 2 min with 0.2% Triton X-100 in PBS, washed, and blocked
for 45 min in blocking buffer (1% BSA in PBS). After 60 min incu-
bation with primary CRMP1 and HSPA1A antibodies, cells were
washed with PBS before addition of secondary antibodies (goat
anti-mouse or anti-rabbit coupled with Alexa Fluor 488 or Alexa
Fluor 594; 1:200 in blocking buffer) for 45 min, followed by
DNA staining with Hoechst 33342 and several washing steps
with PBS. Images were recorded using a Leica SP2 confocal micro-
scope.Microscope settingswere carefully chosen to be able to com-
pare the fluorescence intensities in the different samples.
In vitro HTT aggregation assays
The proteins His-CRMP1, His-CRMP1-D408V, and His-HSPA1A
were expressed in E. coli BL21-Codon PlusTM RP (Stratagene)
and purified to ∼95% homogeneity using Ni-NTA agarose beads.
For monitoring the effects of modulator proteins on spontaneous
polyQ-mediated HTT aggregation, purified GST-HTTQ49 fusion
proteinwas centrifuged for 40min (200,000g) at 4°C to remove po-
tential preformed insoluble protein aggregates. Then, the fusion
protein (2 µM) was incubated at 20°C (300 rpm) in aggregation
buffer (50 mM Tris/HCl, pH 7.4, 150 mM NaCl and 1 mM EDTA,
1 mM DTT) with PreScission Protease (2 units/µL; GE Healthcare)
as well as with potential modifier proteins (BSA, CRMP1, CRMP1-
D408V or HSPA1A; 16 µM). Formation of SDS-stable HTTQ49 pro-
tein aggregates was quantified by filter retardation assays (Wanker
et al. 1999). For dot-blot analysis, 3 µL (250 ng) of each aggregation
reaction was filtered onto a nitrocellulose membrane (Whatman,
Protran BA85 0.2 µm), and insoluble HTTQ49 aggregates retained
on filter membranes were detected using the CAG53b antibody
(1:5000). Soluble, HTTQ49 molecules were detected with the
monoclonal antibody 3B5H10 (1:5000; Sigma). Signal intensities
were quantified using the AIDA Image Analyzer v3.21 software.
High-content fluorescence microscopy
SH-EP cells were grown at 37°C and 5% CO2 in Dulbecco’s modi-
fied Eaglemedium (DMEM) supplemented with 4.5 g/L D-glucose,
10% fetal calf serum, penicillin (100 units/mL) and streptomycin
(100 μg/mL) in 96-well cell culture plates (10,000 cells/well) and
cotransfected (GeneJet, SignaGen) with an equimolar mix of
cDNAs encoding YFP-HTTex1Q79 and mCherry-tagged modifiers
(100 ng each). Forty-eight hours post-transfection, arrayed cells
were fixed with 4% paraformaldehyde in 1× PBS, containing
Hoechst 33342 adjusted to a final concentration of 1:2500. After
15 min incubation at room temperature, cells were washed twice
with 1× PBS. Afterward, cells were permeabilized with 0.2%
Triton X-100 for 2 min. Then, cells were blocked with 1% BSA in
1× PBS for 45 min and incubated with the MW8 antibody
(1:500, diluted in 1% BSA) overnight at 4°C. After overnight incu-
bation, cells were washed three times with 1× PBS to remove un-
bound primary antibody. Thereafter, cells were incubated with
the goat anti-mouse Cy5-conjugated secondary antibody (Invitro-
gen) (1:200, diluted in 1% BSA) for 1 h at room temperature. Final-
ly, cells were washed three times with 1× PBS and analyzed on the
Cellomics instrument, named ArrayScan VTI (Thermo Scientific)
using the ArrayScan VTI software. Individual SH-EP cells were
identified through the fluorescence of the nucleus dye Hoechst
33342. Afterward, double-transfected cells were identified via
the YFP fluorescence. Besidesmeasuring the total YFP fluorescence
of the YFP-HTTex1Q79 protein, YFP-HTTex1Q79 aggregates were
quantified via the Spot YFP fluorescence method in the imaging
analysis protocol. In addition, the mCherry fluorescence was mea-
sured to quantify mCherry-tagged proteins in cells. The Cy5 fluo-
rescence of a secondary Cy5 conjugated antibodywasmeasured to
quantify YFP-HTTex1Q79 aggregates via the MW8 antibody.
Drosophila experiments
For analysis of retina degeneration, heads of 2- to 3-d-old females
(10–20 heads per genotype) were fixed for 48 h (Bouin’s fixative;
Sigma-Aldrich), and vertical 10-µm semithin paraffin sections
were analyzed tomeasure the absolute retina extension using light
microscopy.
For detection of HTT aggregates in flies, eye/antennal imagi-
nal discs of third instar wandering larvae were prepared in Ringer’s
solution and fixed in 4% formaldehyde for 30 min. Subsequently,
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imaginal discs were washed 5 × 5min and 1 × 30min with PBT. Af-
ter preincubation in PBT/NGS for 1 h, primary antibodies (1-82,
7E8A10, and rabbit anti-MYC)were added (1:200) for overnight in-
cubation.HTTaggregateswere detected using themousemonoclo-
nal anti-HTT antibody 1-82 (Millipore). Neuronal photoreceptor
precursor cells were identified using the rat monoclonal anti-elav
antibody 7E8A10 (Developmental Studies Hybridoma Bank), and
MYC-CRMP1 protein was recognized using a rabbit anti-MYC an-
tibody. Then, imaginal discs were washed again in PBT and incu-
bated for 4 h in PBT/NGS, including secondary antibodies (anti-
rabbit Alexa Fluor 488, anti-mouse Alexa Fluor 555 [Invitrogen],
anti-rat Cy5 [Dianova], 1:200). After washing, DNA was stained
with Hoechst 33258 (Sigma-Aldrich), and HTT aggregates were de-
termined in a field of 35.71 µm2 in the middle of the posterior
third of the eye/antennal imaginal disc using a Zeiss LSM 510
META confocalmicroscope.One fieldwas analyzed per individual.
For analysis of motor activity, flies with clipped wings were
tested individually in a glass cylinder. Starting with 2-day-old fe-
males, the distance flies can readily climb up in a glass tube within
10 sec was quantified in triplicates every 2 d.
A detailed description of theDrosophila stocks used and geno-
types is provided in the Supplemental Material and Methods.
Data access
We have established a web server (http://artemis.mdc-berlin.de/
crmp1/ppi_search.php) to highlight network proteins and their
direct and indirect interaction partners within interaction net-
works (Supplemental Tables S1–S12).
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